Versant Capital Management’s Nurix Therapeutics NRIX Stock Holding History
Bought
Maintained
Sold
Other funds holding NRIX
BBA
Versant Capital Management's NRIX Position: Q3 2026 in Review
Versant Capital Management held its Nurix Therapeutics (NRIX) position steady in Q3 2026 at 61 shares worth $1.45K. The position accounts for ﹤0.01% of the portfolio, ranked #2657.
Versant Capital Management first reported a position in NRIX in Q2 2026 and has held it in 2 quarters since. The position peaked at $1.48K in Q2 2026. 234 funds tracked by Wall St. Rank hold NRIX as of Q3 2026.
- Versant Capital Management held 61 shares of Nurix Therapeutics worth $1.45K as of Q3 2026.
- Versant Capital Management left its Nurix Therapeutics share count unchanged in Q3 2026.
- Nurix Therapeutics made up ﹤0.01% of Versant Capital Management's portfolio in Q3 2026, its #2657 holding.
- Versant Capital Management first reported a position in Nurix Therapeutics in Q2 2026 and has held it in 2 quarters since.
- Versant Capital Management's Nurix Therapeutics position peaked at $1.48K in Q2 2026.
- 234 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q3 2026.
Based on Versant Capital Management's 13F filing for Q3 2026, filed 2 Oct 2026.